The need for effective pancreatic cancer detection and management: a biomarker-based strategy

References

• Dodson LF, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011;3(4):517-37
   PubMed Web of Science ®Google Scholar
• Güngör C, Hofmann BT, Wolters-Eisfeld G, et al. Pancreatic cancer. Br J Pharmacol 2014;171:849-58
   PubMed Web of Science ®Google Scholar
• Xu Z, Pothula SP, Wilson JS, et al. Pancreatic cancer and its stroma: a conspiracy theory. World J Gastroenterol 2014;20(32):11216-29
   PubMed Web of Science ®Google Scholar
• Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol 2015;8:44
   Google Scholar
• Ujiki MB, Talamonti MS. Surgical management of pancreatic cancer. Semin Radiat Oncol 2005;15(4):218-25
   PubMed Web of Science ®Google Scholar
• Jazieh KA, Foote MB, Diaz LA. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma. Semin Radiat Oncol 2014;24(2):67-76
   PubMed Web of Science ®Google Scholar
• Bissolati M, Sandri MT, Burtulo G, et al. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. Tumor Biol 2015;36(2):991-6
   PubMed Web of Science ®Google Scholar
• Li HY, Cui ZM, Chen J, et al. Pancreatic cancer: diagnosis and treatments. Tumour Biol 2015;36:1375-84
   PubMed Web of Science ®Google Scholar
• Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008;3:157-88
   PubMed Web of Science ®Google Scholar
• Lowery MA, O’Reilly EM. Pancreatic cancer: the role of molecular markers in diagnosis and management. Clin Adv Hematol and Oncol 2011;9(12):900-8
   PubMedGoogle Scholar
• Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J (United States) 2012;18(6):530-8
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics. 2014. Ca Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Wang Y, Duan H, Yang X, et al. Cigarette smoking and the risk of pancreatic cancer: a case-control study. Med Oncol 2014;31(10):184
   PubMed Web of Science ®Google Scholar
• Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. Ca Cancer J Clin 2013;63:318-48
   PubMed Web of Science ®Google Scholar
• Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet 2004;363:1049-57
   PubMed Web of Science ®Google Scholar
• Fiorino S, Chili E, Bacchi-Reggiani L, et al. Association between hepatitis B or hepatitis C virus infection and risk of pancreatic adenocarcinoma development: a systemic review and meta-analysis. Pancreatology 2013;13:147-60
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009;101:424-31
   PubMed Web of Science ®Google Scholar
• Stoita A, Penman ID, Williams DB. Review of screening for pancreatic cancer in high risk individuals. World J Gastroenterol 2011;17(19):2365-71
   PubMed Web of Science ®Google Scholar
• Saiki Y, Horii A. Molecular pathology of pancreatic cancer. Pathol Int 2014;64:10-19
   PubMed Web of Science ®Google Scholar
• Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis 2010;28(4-5):645-56
   PubMed Web of Science ®Google Scholar
• Lucas AL, Frado LE, Hwang C, et al. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer 2014;120(13):1960-7
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015;6:6744
   PubMed Web of Science ®Google Scholar
• Müller S, Raulefs S, Bruns P, et al. Next-generation sequencing reveals novel differentially regulated mRNAs, IncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Mol Cancer 2015;14:94
   Google Scholar
• Wang J, Paris PL, Chen J, et al. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett 2015;356:404-9
   PubMed Web of Science ®Google Scholar
• Regel I, Kong B, Raulefs S, et al. Energy metabolism and proliferation in pancreatic carcinogenesis. Langenbecks Arch Surg 2012;397:507-12
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Gironella M, Castells A, et al. Molecular markers in pancreatic cancer diagnosis. Clin Chim Acta 2013;418:22-9
   PubMed Web of Science ®Google Scholar
• Distler M, Aust D, Weitz J, et al. Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. BioMed Res Int 2014;474905
   Google Scholar
• Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17
   PubMed Web of Science ®Google Scholar
• Merika EE, Syrigos KN, Saif MW. Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol Res Pract 2012;Article 1D 781765
   Google Scholar
• de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol 2014;741:8-16
   PubMed Web of Science ®Google Scholar
• Gore J, Korc M. Pancreatic cancer stroma: friend or foe? Cancer Cell 2014;25(6):711-712
   PubMed Web of Science ®Google Scholar
• Habisch H, Zhou S, Siech M, et al. Interaction of stellate cells with pancreatic carcinoma cells. Cancers 2010;2:1661-82
   PubMedGoogle Scholar
• Whatcott CJ, Posner RG, Von Hoff DD, et al. Desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ, Munshi HG, editors. Pancreatic Cancer and Tumor Microenvironment. Transworld Research Network; Trivandrum, India: 2012
   Google Scholar
• Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Gene Dis 2015;2:133-43
   PubMed Web of Science ®Google Scholar
• Moniaux N, Andrianifahana M, Brand RE, et al. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 2004;91:1633-83
   PubMed Web of Science ®Google Scholar
• Edge S, Byrd DR, Compton CC, et al. American Joint Committee on Cancer. AJCC Cancer Staging Handbook. 7th edition. Springer; New York, NY: 2010
   Google Scholar
• Tamm EP, Balachandran A, Bhosale PR, et al. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am 2012;50:407-28
   PubMed Web of Science ®Google Scholar
• Kaltsas S, Syrigos KN, Saif MW. Pancreatic cancer in 2014. JOP. J Pancreas (Online) 2014;15(2):84-86
   PubMedGoogle Scholar
• Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013;62:317-26
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Croce CM. Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer? JAMA 2014;311(4):363-5
   PubMed Web of Science ®Google Scholar
• Saif MW. Advanced stage pancreatic cancer: novel therapeutic options. Expert Rev Clin Pharmacol 2014;7(4):487-98
   PubMed Web of Science ®Google Scholar
• Saif MW. Advancements in the management of pancreatic cancer: 2013. JOP 2013;14(2):112-18
   PubMedGoogle Scholar
• Chames P, Kerfelec B, Baty D. Therapeutic antibodies for the treatment of pancreatic cancer. Sci World J 2010;10:1107-20
   Web of Science ®Google Scholar
• Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012;38:843-53
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. JCO 2009;27(33):5513-18
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 2007;25(18S):Abstract 4508
   Google Scholar
• Yang ZY, Yuan JQ, Zheng DY, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One 2013;8(3):e57528
   PubMed Web of Science ®Google Scholar
• FDA. Development tools qualification programs. DDT Glossary. Available from: www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284395.htm
   Google Scholar
• McPartlin DA, O’Kennedy RJ. Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations. Expert Rev Mol Diagn 2014;14(8):979-98
   PubMed Web of Science ®Google Scholar
• Malati T. Tumour markers: an overview. Indian J Clin Biochem 2007;22(2):17-31
   PubMedGoogle Scholar
• Fitzgerald S, Sheehan KM, O’Grady A, et al. Relationship between epithelial and stromal TRIM28 expression predicts survival in colorectal cancer patients. J Gastroenterol Hepatol 2013;28:967-74
   PubMed Web of Science ®Google Scholar
• Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 2013;107:15-22
   PubMed Web of Science ®Google Scholar
• Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointestinal Oncol 2012;3(2):105-99
   PubMedGoogle Scholar
• Sharma S. Tumor markers in clinical practice: general principles and guidelines. Indian J Med Paediatr Oncol 2009;30(1):1-8
   PubMedGoogle Scholar
• Shaw VE, Lane B, Jenkinson C, et al. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer 2014;13:114
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract 2013;22:4-11
   PubMed Web of Science ®Google Scholar
• Poruk KE, Firpo MA, Adler DG, et al. Screening for pancreatic cancer: why, how and who? Ann of Surg 2013;257(1):17-26
   PubMed Web of Science ®Google Scholar
• Duffy M.J, Sturgeon C, Lamerz R, et al.Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann of Oncol 2010;21:441-7
   PubMed Web of Science ®Google Scholar
• Passerini R, Cassatella MC, Boveri S, et al. The pitfalls of CA19-9; routine testing and comparison of two automated immunoassays in a Reference Oncology Center. Am J Clin Pathol 2012;138:281-7
   PubMed Web of Science ®Google Scholar
• Satake K, Takeuchi T, Homma T, et al. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994;9:703-6
   PubMed Web of Science ®Google Scholar
• Kim JE, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19(2):182-6
   PubMed Web of Science ®Google Scholar
• Steinberg W. The clinical utility of the CA 19-9 tumor associated antigen. Am J Gastroenterol 1990;85:350-5
   PubMed Web of Science ®Google Scholar
• Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. EJSO 2007;33:266-70
   PubMed Web of Science ®Google Scholar
• Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumor Biol 2014;35:7459-65
   PubMed Web of Science ®Google Scholar
• Hernandez JM, Cowgill SM, Al-Saadi S, et al. CA19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg 2009;13:349-53
   PubMed Web of Science ®Google Scholar
• Zhang L, Farrell JJ, Zhou H, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 2010;138(3):949-957
   PubMed Web of Science ®Google Scholar
• Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006;5:787-96
   PubMed Web of Science ®Google Scholar
• Drakaki A, Iliopoulos D. MicroRNA-gene signaling pathways in pancreatic cancer. Biomed J 2013;36(5):200-8
   PubMedGoogle Scholar
• di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013;144:1220-9
   PubMed Web of Science ®Google Scholar
• Rivlin N, Brosh R, Oren M, et al. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Gene Cancer 2011;2(4):466-74
   PubMedGoogle Scholar
• Sturm PD, Hruban RH, Ramsoekh TB, et al. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998;186(3):247-53
   PubMed Web of Science ®Google Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009;60:167-79
   PubMed Web of Science ®Google Scholar
• Schultz NA, Dehlendorff C, Jenson BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014;311(4):392-404
   PubMed Web of Science ®Google Scholar
• Liu R, Chen X, Du Y, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012;58(3):610-18
   PubMed Web of Science ®Google Scholar
• Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009;2(9):807-13
   PubMed Web of Science ®Google Scholar
• Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 2012;131(3):683-91
   PubMed Web of Science ®Google Scholar
• Schultz NA, Werner J, Wilenbrock H, et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol 2012;25(12):1609-22
   PubMed Web of Science ®Google Scholar
• Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901-8
   PubMed Web of Science ®Google Scholar
• Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumor Biol 2013;34(6):3279-92
   PubMed Web of Science ®Google Scholar
• Gayral M, Jo S, Hanoun N, et al. MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol 2014;20(32):11199-209
   PubMed Web of Science ®Google Scholar
• Zhong X, Coukos G, Zhang L. MiRNAs in human cancer. Methods Mol Biol 2012;822:295-306
   PubMedGoogle Scholar
• Ding Z, Wu H, Zhang J, et al. MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles. Tumor Biol 2014;35:8837-48
   PubMed Web of Science ®Google Scholar
• Singh S, Chitkara D, Kumar V, et al. MiRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett 2013;334:211-20
   PubMed Web of Science ®Google Scholar
• Nolen BM, Brand RE, Prosser D, et al. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS One 2014 9(4):e94928
   Google Scholar
• Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metast Rev 2013;32(3-4):643-71
   PubMed Web of Science ®Google Scholar
• Poruk KE, Firpo MA, Scaife CL, et al. Serum osteopontin and TIMP-1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 2013;42(2):193-197
   PubMed Web of Science ®Google Scholar
• Torres MP, Chakraborty S, Souchek J, et al. Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des 2012;18(17):2472-81
   PubMed Web of Science ®Google Scholar
• Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer 2014;13:129
   PubMed Web of Science ®Google Scholar
• Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009;15(14):4674-9
   PubMed Web of Science ®Google Scholar
• Roberts AS, Campa MJ, Gottlin EB, et al. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a Phase 3 trial (Cancer and Leukemia Group B 80303). Cancer 2012;118(2):571-8
   PubMed Web of Science ®Google Scholar
• Takadate T, Onogawa T, Fukuda T, et al. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer 2013;132:1368-82
   PubMed Web of Science ®Google Scholar
• Cheng WF, Huang CY, Chang MC, et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer 2009;100:1144-53
   PubMed Web of Science ®Google Scholar
• Hassan R, Laszik ZG, Lerner M, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45
   PubMed Web of Science ®Google Scholar
• Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem 2013;13(2):276-280
   PubMed Web of Science ®Google Scholar
• Hassan R, Tapan B, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42
   PubMed Web of Science ®Google Scholar
• Johnston FM, Tan MCB, Tan BRJr, et al. Circulating mesothelin protein and cellular anti-mesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009;15:6511-18
   PubMed Web of Science ®Google Scholar
• Byrne H, Conroy PJ, Whisstock JC, et al. A tale of two specificities; bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013;31(11):621-32
   PubMed Web of Science ®Google Scholar
• Chang MC, Chen CA, Hsieh CY, et al. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem J 2009;424:449-58
   PubMed Web of Science ®Google Scholar
• Chen S, Hung W, Wang P, et al. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep 2013;3:1870
   PubMed Web of Science ®Google Scholar
• Walsh N, Clynes M, Crown J, et al. Alterations in integrin expression modulates invasion of pancreatic cancer cells. J Exp Clin Cancer Res 2009;28:140
   PubMed Web of Science ®Google Scholar
• Philips PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 2007;25:4509
   Web of Science ®Google Scholar
• Boeck S, Jung A, Laubender RP, et al. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer 2013;108(2):469-76
   PubMed Web of Science ®Google Scholar
• Sjoquist KM, Chin VT, Chantrill LA, et al. Personalising pancreas cancer treatment; when tissue is the issue. World J Gastroenterol 2014;20(24):7849-7863
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP, Keating GM, Scott LJ. Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 2010;70(2):215-39
   PubMed Web of Science ®Google Scholar
• Vrijenhoek T, Kraaijeveld K, Elferink M, et al. Next-generation sequencing-based genome diagnostics across clinical genetics centers: implementation choices and their effects. Eur J Hum Genet 2015. [Epub ahead of print]
   Google Scholar
• Mardis ER. Applying next-generation sequencing to pancreatic cancer treatment. Nat Rev Gastroenterol and Hepatol 2012;9:477-86
   PubMed Web of Science ®Google Scholar
• Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 2011;32:177-95
   PubMedGoogle Scholar
• Liang WS, Craig DW, Carpten J, et al. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One 2012;7(10):e43192
   PubMed Web of Science ®Google Scholar
• Amato E, dal Molin M, Mafficini A, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 2014;233:217-27
   PubMed Web of Science ®Google Scholar
• Pilarsky C, Grützmann R. Analysis of DNA methylation in pancreatic cancer: an update. Methods Mol Biol 2015;1238:173-81
   PubMedGoogle Scholar
• Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010;70:27-56
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Kitamoto S, Higashi M, et al. Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice. PLoS One 2014;9(4):e93760
   PubMed Web of Science ®Google Scholar
• Yao F, Sun M, Dong M, et al. NPTX2 hypermethylation in pure pancreatic juice predicts pancreatic neoplasms. Am J Med Sci 2013;346(3):175-80
   PubMed Web of Science ®Google Scholar
• Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006;66(2):1208-17
   PubMed Web of Science ®Google Scholar
• Neale RE, Clark PJ, Fawcett J, et al. Association between hypermethylation of DNA repetitive elements in white blood cell DNA and pancreatic cancer. Cancer Epidemiol 2014;38:576-82
   PubMed Web of Science ®Google Scholar
• Madhavan B, Yue S, Galli U, et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer 2015;136:2616-27
   PubMed Web of Science ®Google Scholar
• Lin J, Li J, Huang B, et al. Exosomes: novel biomarkers for clinical diagnosis. Sci World J 2015;Article ID:657086
   Google Scholar
• Garcia-Contreras M, Ricordi C, Robbins PD, et al. Exosomes in the pathogenesis, diagnosis and treatment of pancreatic diseases. CellR4 2014;2(1):e807
   Google Scholar
• Lau C, Kim Y, Chia D, et al. Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem 2013;288(37):26888-97
   PubMed Web of Science ®Google Scholar
• Lee JC, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol 2008;26(17):2806-12
   PubMed Web of Science ®Google Scholar
• Hou YC, Chao YJ, Tung HL, et al. Coexpression of CD44-positive/CD33-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Cancer 2014;120(17):2766-77
   PubMed Web of Science ®Google Scholar
• Tanase CP, Neagu AI, Necula LG, et al. Cancer stem cells : involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. World J Gastroenterol 2014;20(31):10790-801
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1(3):313-23
   PubMed Web of Science ®Google Scholar
• Tjensvoll K, Nordgård O, et al. Circulating tumor cells in pancreatic cancer patients: method of detection and clinical implications. Int J Cancer 2014;134:1-8
   PubMed Web of Science ®Google Scholar
• Fitzgerald TL, McCubrey JA. Pancreatic stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Adv Biol Regul 2014;56:45-50
   Google Scholar
• Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab 2014;51(3):160-71
   PubMed Web of Science ®Google Scholar
• Chan A, Prassas I, Dimitromanolakis A, et al. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res 2014;20(22):5787-95
   PubMed Web of Science ®Google Scholar
• Chen R, Dawson DW, Pan S, et al. Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. Lab Invest 2015;95(1):43-55
   PubMed Web of Science ®Google Scholar
• Krasnoslobodtsev AV, Torres MP, Kaur S, et al. Nano-immunoassay with improved performance for detection of cancer biomarkers. Nanomed Nanotech Biol Med 2015;11:167-73
   PubMed Web of Science ®Google Scholar
• Collins MA, di Magliano MP. Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol 2014;4:00407
   Google Scholar
• Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. BBA-Gen Subjects 2012;1820(9):1347-53
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang X, Zhao P, et al. Development and characterization of monoclonal antibodies against pancreatic cancer marker hippocalcin-like 1 protein. Monocl Antib Immunodiagn Immunother 2014;33(1):20-27
   Google Scholar
• Bünger S, Laubert T, Roblick UJ. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 2011;137:375-89
   PubMed Web of Science ®Google Scholar